Should You Buy Novartis Stock Before October 28? - Yahoo Finance

Novartis AG ( / NVS ) remains a core consideration for healthcare-focused investors in 2026, balancing a 3.24% dividend yield against significant generic competition for its blockbuster drugs. While the company recently reported a 5% decline in Q1 sales due to patent expirations, management has reaffirmed its 2026 guidance , projecting a rebound in the second half of the year. Novartis AG (NOVN) CHF 108.50 5.14% since Jan 5, 2026 As of Apr 27, 18:30 GMT+3 • Disclaimer Apr 27, 2026 Open113.52 Mkt cap$291.76B USD 52-wk high131.00 High114.30 P/E ratio20.33 52-wk low87.89 Div yield3.24% Investment Thesis: Why Buy Novartis?

Recommended Industries

Transportation

Transit

Education

EMS

Utilities

Government

Healthcare

Hospitality

Public Safety

Public Works

Event Management

Waste Management

Buy Novartis Stock -

Should You Buy Novartis Stock Before October 28? - Yahoo Finance

Novartis AG ( / NVS ) remains a core consideration for healthcare-focused investors in 2026, balancing a 3.24% dividend yield against significant generic competition for its blockbuster drugs. While the company recently reported a 5% decline in Q1 sales due to patent expirations, management has reaffirmed its 2026 guidance , projecting a rebound in the second half of the year. Novartis AG (NOVN) CHF 108.50 5.14% since Jan 5, 2026 As of Apr 27, 18:30 GMT+3 • Disclaimer Apr 27, 2026 Open113.52 Mkt cap$291.76B USD 52-wk high131.00 High114.30 P/E ratio20.33 52-wk low87.89 Div yield3.24% Investment Thesis: Why Buy Novartis?

Contact Air Comm today and let us find the ideal solution for you.

Contact Us